Spain Country Drug Report 2019

Key statistics

Most recent estimates and data reported

  EU range
  Year Country data Min. Max.

 

Cannabis
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 26.6 6.51 36.79
Last year prevalence of use — young adults (%) 2017 18.3 1.8 21.8
Last year prevalence of drug use — all adults (%) 2017 11 0.9 11
All treatment entrants (%) 2016 29.2 1.03 62.98
First-time treatment entrants (%) 2016 40.7 2.3 74.36
Quantity of herbal cannabis seized (kg) 2017 34 517 11.98 94 378.74
Number of herbal cannabis seizures 2017 151 968 57 151 968
Quantity of cannabis resin seized (kg) 2017 334 919 0.16 334 919
Number of cannabis resin seizures 2017 157 346 8 157 346
Potency — herbal (% THC) (minimum and maximum values registered) n.a. n.a. 0 65.6
Potency — resin (% THC) (minimum and maximum values registered) n.a. n.a. 0 55
Price per gram — herbal (EUR) (minimum and maximum values registered) n.a. n.a. 0.58 64.52
Price per gram — resin (EUR) (minimum and maximum values registered) n.a. n.a. 0.15 35
Cocaine
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 2.1 0.85 4.85
Last year prevalence of use — young adults (%) 2017 2.8 0.1 4.7
Last year prevalence of drug use — all adults (%) 2017 2.2 0.1 2.7
All treatment entrants (%) 2016 39.2 0.14 39.2
First-time treatment entrants (%) 2016 39.7 0 41.81
Quantity of cocaine seized (kg) 2017 40 960 0.32 44 751.85
Number of cocaine seizures 2017 42 206 9 42 206
Purity (%) (minimum and maximum values registered) n.a. n.a. 0 100
Price per gram (EUR) (minimum and maximum values registered) n.a. n.a. 2.11 350
Amphetamines
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 1.3 0.84 6.46
Last year prevalence of use — young adults (%) 2017 0.9 0 3.9
Last year prevalence of drug use — all adults (%) 2017 0.5 0 1.8
All treatment entrants (%) 2016 1.7 0 49.61
First-time treatment entrants (%) 2016 1.9 0 52.83
Quantity of amphetamine seized (kg) 2017 198 0 1 669.42
Number of amphetamine seizures 2017 3 886 1 5 391
Purity — amphetamine (%) (minimum and maximum values registered) n.a. n.a. 0.07 100
Price per gram — amphetamine (EUR) (minimum and maximum values registered) n.a. n.a. 3 156.25
MDMA
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 1 0.54 5.17
Last year prevalence of use — young adults (%) 2017 1.2 0.2 7.1
Last year prevalence of drug use — all adults (%) 2017 0.6 0.1 3.3
All treatment entrants (%) 2016 0.2 0 2.31
First-time treatment entrants (%) 2016 0.3 0 2.85
Quantity of MDMA seized (tablets) n.a. 363 138 159 8 606 765
Number of MDMA seizures 2017 3 569 13 6 663
Purity (MDMA mg per tablet) (minimum and maximum values registered) n.a. n.a. 0 410
Purity (MDMA % per tablet) (minimum and maximum values registered) n.a. n.a. 2.14 87
Price per tablet (EUR) (minimum and maximum values registered) n.a. n.a. 1 40
Opioids
High-risk opioid use (rate/1 000) 2016 2.2 0.48 8.42
All treatment entrants (%) 2016 26.8 3.99 93.45
First-time treatment entrants (%) 2016 13.3 1.8 87.36
Quantity of heroin seized (kg) 2017 524 0.01 17 385.18
Number of heroin seizures 2017 7 283 2 12 932
Purity — heroin (%) (minimum and maximum values registered) n.a. n.a. 0 91
Price per gram — heroin (EUR) (minimum and maximum values registered) n.a. n.a. 5 200
Newly diagnosed HIV cases related to injecting drug use (cases/million population, Source: ECDC) 2017 2.3 0 47.8
HIV prevalence among PWID* (%) 2016 31.1 0 31.1
HCV prevalence among PWID* (%) 2016 64.4 14.7 81.5
Injecting drug use (cases rate/1 000 population) 2016 0.41 0.08 10.02
Drug-induced deaths — all adults (cases/million population) 2016 15.7 2.44 129.79
Health and social responses
Syringes distributed through specialised programmes 2016 1 503 111 245 11 907 416
Clients in substitution treatment 2016 58 749 209 178 665
Treatment demand
All entrants 2016 45 637 179 118 342
First-time entrants 2016 22 816 48 37 577
All clients in treatment 2016 186 339 1 294 254 000
Drug law offences
Number of reports of offences 2017 389 229 739 389 229
Offences for use/possession 2017 376 282 130 376 282

Spain main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.